wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q26823305-3D8423C9-EFE3-4431-BC3F-2FF356546981
Q26823305-3D8423C9-EFE3-4431-BC3F-2FF356546981
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26823305-3D8423C9-EFE3-4431-BC3F-2FF356546981
The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)
P2860
Q26823305-3D8423C9-EFE3-4431-BC3F-2FF356546981
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26823305-3D8423C9-EFE3-4431-BC3F-2FF356546981
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5ed32eb4073d8811c86ce22d076deb0a68f8d0d6
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.